NON-HODGKIN LYMPHOMA

This early-stage study tested an oral drug called HMPL-523 in 69 adults with lymphoma that had returned or stopped responding to other treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was stopped early, so re…

This early-stage study tested a combination of two drugs, tafasitamab and parsaclisib, in 54 adults with relapsed or treatment-resistant non-Hodgkin lymphoma or chronic lymphocytic leukemia. The main goals were to check safety and find the right dose. The study was terminated ear…

This study tested a new drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma that had spread or come back after other treatments. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early,…

This study tested a new drug called IPH6501 in 23 people with a type of blood cancer (Non-Hodgkin lymphoma) that had returned or stopped responding to other treatments. The main goal was to check the drug's safety and find the best dose. The trial was stopped early, so results ar…

This early-stage study tested an experimental oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had come back. The main goals were to check safety, how the drug moves through the body, and find the right dose. The study was stopped early, so result…

This study tested a one-time treatment using CRISPR-edited immune cells from a donor (CTX110) in 93 adults with B-cell cancers like lymphoma or leukemia that had come back or stopped responding to other treatments. The goal was to see if these cells were safe and could shrink tum…

This early-stage study tested a new drug called AUR103 Calcium in 27 adults with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and see how the drug worked in the body. The trial was terminated early, so no final results are …

This early-phase trial tested a two-step radiation treatment for people with non-Hodgkin lymphoma that had come back or stopped responding to standard therapies. The treatment uses a special protein to deliver radiation directly to cancer cells. Only one person took part before t…

This early-stage trial tested a new drug called GEN3017 in 9 people with CD30-positive Hodgkin or Non-Hodgkin lymphoma that had returned or stopped responding to other treatments. The goal was to check the drug's safety and how well the body tolerates it. The study was terminated…

This study looked at whether a simple, 5-minute daily breathing exercise using a handheld device, combined with a personalized exercise plan, could improve heart health and fitness in people who have finished treatment for lymphoma. The study aimed to recruit lymphoma survivors a…